With a distinguished career in technology and finance, Taro Kuriyama has made significant contributions as an entrepreneurial founder. He is known for his role in launching innovative tech-driven initiatives that bridge the gap between digital transformation and investment opportunities. His deep understanding of market trends positions him uniquely to leverage emerging technologies within traditional financial frameworks. By actively engaging with startups, Taro plays a pivotal role in guiding new ventures towards scalable growth while fostering collaborative partnerships across sectors. His insights into market dynamics have proven invaluable to both emerging entrepreneurs and seasoned investors alike.
With a distinguished career in technology and finance, Taro Kuriyama has made significant contributions as an entrepreneurial founder. He is known for his role in launching innovative tech-driven initiatives that bridge the gap between digital transformation and investment opportunities. His deep understanding of market trends positions him uniquely to leverage emerging technologies within traditional financial frameworks. By actively engaging with startups, Taro plays a pivotal role in guiding new ventures towards scalable growth while fostering collaborative partnerships across sectors. His insights into market dynamics have proven invaluable to both emerging entrepreneurs and seasoned investors alike.
The investment outlook of Taro Kuriyama emphasizes innovation as a key driver of growth. Focused on fostering new technologies, he actively seeks out opportunities that align with his vision for disruptive advancement in traditional sectors. His approach not only highlights the importance of market adaptability but also promotes strategic collaboration among stakeholders to cultivate emerging business models. By championing tech-savvy entrepreneurs, he aids in navigating complex competitive landscapes while positioning ventures for long-term success and scalability. This blend of forward-thinking insight and entrepreneurial spirit uniquely defines his strategy.
The investment outlook of Taro Kuriyama emphasizes innovation as a key driver of growth. Focused on fostering new technologies, he actively seeks out opportunities that align with his vision for disruptive advancement in traditional sectors. His approach not only highlights the importance of market adaptability but also promotes strategic collaboration among stakeholders to cultivate emerging business models. By championing tech-savvy entrepreneurs, he aids in navigating complex competitive landscapes while positioning ventures for long-term success and scalability. This blend of forward-thinking insight and entrepreneurial spirit uniquely defines his strategy.
| Trades 8151 | Longs Won 3999/8151 49% | Profit Factor 1.92 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $192,203.64 |
| Average Win $99,363.59 | Best Trade (Jun 30) $5.93M | Sharpe Ratio -8.6 |
| Average Loss -$49,899.08 | Worst Trade (Sep 02) -$1.76M | Z-Score -12.87 (100%) |
| Commissions $0 | Avg. Trade Length 4m 2w 4d | Expectancy $23,358.42 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 18,519 | 16,667 | 14,815 | 12,963 | 11,111 | 9,259 | 7,407 | 5,556 | 3,704 | 1,852 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AA Alcoa Corporation | 29,532 | $1.54M | $1.4M | - | -$137,618.64 | -8.94% | -0.44% |
AAL American Airlines Group Inc. | 162,249 | $1.79M | $2.64M | - | $842,542.94 | 46.96% | -1.99% |
ABBV AbbVie Inc. | 2,437 | $613,247 | $594,140.6 | - | -$19,106.4 | -3.12% | -0.975% |
ABNB Airbnb, Inc. | 5,251 | $663,096.24 | $800,725.04 | - | $137,628.8 | 20.76% | 0.0 |
ABOS Acumen Pharmaceuticals, Inc. | 24,426 | $57,645.09 | $54,714.24 | - | -$2,930.85 | -5.08% | 0.0 |
ABSI Absci Corporation | 36,000 | $138,809.02 | $280,080 | - | $141,270.98 | 101.77% | -7.381% |
ABT Abbott Laboratories | 40,657 | $3.74M | $4.29M | - | $550,214.5 | 14.72% | -0.236% |
ABUS Arbutus Biopharma Corporation | 25,055 | $120,264 | $108,738.7 | - | -$11,525.3 | -9.58% | -6.061% |
ACCO Acco Brands Corporation | 14,242 | $59,247 | $62,095.12 | - | $2,848.12 | 4.81% | 0.0 |
ACDC ProFrac Holding Corp. | 45,301 | $279,116.49 | $183,016.04 | - | -$96,100.45 | -34.43% | -10.322% |
ACET Adicet Bio, Inc. | 10,991 | $89,137.01 | $100,677.56 | - | $11,540.55 | 12.95% | 0.0 |
ACGL Arch Capital Group Ltd | 8,338 | $809,286 | $829,797.76 | - | $20,511.76 | 2.53% | +0.434% |
ACHR Archer Aviation Inc. | 143,693 | $715,194.82 | $747,203.6 | - | $32,008.78 | 4.48% | 0.0 |
ACHV Achieve Life Sciences Inc. | 25,173 | $109,808.28 | $162,869.31 | - | $53,061.03 | 48.32% | -2.853% |
ACIU Acimmune SA | 10,398 | $24,747 | $23,603.46 | - | -$1,143.54 | -4.62% | -0.873% |
ACIW ACI Worldwide, Inc. | 19,434 | $906,790.44 | $1.07M | - | $167,521.08 | 18.47% | -4.343% |
ACM Aecom | 27,487 | $2.33M | $2.08M | - | -$249,307.07 | -10.69% | +1.135% |
ACMR Acm Research Inc. | 4,089 | $518,853 | $326,711.1 | - | -$192,141.9 | -37.03% | 0.0 |
ACN Accenture plc Class A | 10,074 | $1.25M | $1.72M | - | $470,153.14 | 37.5% | +0.223% |
ADC Agree Realty Corporation | 16,105 | $1.22M | $1.23M | - | $5,475.43 | 0.45% | 0.0 |